Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 10, 2006 Stephen D. Simpson	Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool August 8, 2007 Ryan Fuhrmann	Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth.
The Motley Fool November 9, 2006 Brian Lawler	Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note.
The Motley Fool November 11, 2004 Brian Gorman	Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring.
The Motley Fool January 26, 2006 Stephen D. Simpson	Little Bits Add Up at Becton Dickinson Nothing flashy here, but consistent performance has delivered exceptional value for this health care and medical technology company. This stock has been nearly a 46-bagger over the past 20 years.
The Motley Fool January 20, 2011 Jeremy Phillips	Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares?
The Motley Fool April 27, 2005 Stephen D. Simpson	Becton, Dickinson's Boring Reliability This broadly diversified medical device company doesn't grow fast, but it is consistent. Investors looking for a stable and dependable company with broad exposure to the medical industry should take a look for themselves at Becton, Dickinson.
BusinessWeek May 31, 2004 Robert Barker	Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs.
The Motley Fool June 2, 2005 Brian Gorman	Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye.
The Motley Fool April 20, 2006 Stephen D. Simpson	More Predictable Unpredictability at ICU Hidden beneath all of the volatility is a pretty decent med-tech business. Recent volatility was the kind that investors like. The stock spiked up as earnings exceeded analyst estimates and the business did a fair bit better than management had projected at the end of last quarter.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares.
The Motley Fool November 9, 2005 Stephen D. Simpson	Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note.
The Motley Fool March 1, 2007 Brian Lawler	Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note.
The Motley Fool July 27, 2007 Brian Orelli	Stability From a Likely Source Becton Dickinson's earnings are solid. The medical device and lab supply company has reported growth in earnings and increases in margins.
The Motley Fool November 3, 2011 Dan Caplinger	Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection.
The Motley Fool April 20, 2006 Stephen D. Simpson	Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough?
The Motley Fool September 22, 2006 Brian Lawler	Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note.
The Motley Fool March 1, 2006 Brian Gorman	Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note.
The Motley Fool January 31, 2006 Stephen D. Simpson	Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting.
The Motley Fool May 13, 2005 Brian Gorman	Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool January 4, 2012	A Brief History of Becton, Dickinson's Returns While the past decade has seen valuations contract, the coming decade could see stable, even expanding, valuations.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool March 10, 2008 Brian Orelli	Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors.
The Motley Fool October 21, 2010 Moser & Hinmon	DRIP Candidate Winner: Becton, Dickinson In a health-care bloodbath, Becton, Dickinson pounds Walgreen to a pulp.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool October 13, 2010 Seth Jayson	From Gross to Net at Becton Dickinson With recent margins exceeding historical averages, medical device company Becton Dickinson looks like it's doing fine.
IndustryWeek September 1, 2006 David Blanchard	Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it.
The Motley Fool May 4, 2006 Stephen D. Simpson	Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility.